Gerry Smith
Biotech Reporter at Bloomberg News
Biotech reporter for @business. Views are my own. Tips: [email protected]
Articles
-
1 week ago |
bloomberg.com | Gerry Smith
The Vertex Pharmaceuticals headquarters in Boston, Massachusetts. (Bloomberg) -- Vertex Pharmaceuticals Inc. said more than 20,000 prescriptions have been dispensed for its new non-addictive painkiller, a sign that the drug is gaining some early traction as it attempts to displace opioids. The company disclosed the prescription tally in its earnings release Monday. It includes both hospital and retail settings from when the drug, Journavx, became available in early March through April 18.
-
1 week ago |
bostonglobe.com | Gerry Smith
Moderna Inc. shares declined after the company’s first-quarter vaccine sales missed estimates and it disclosed a delay in the US regulatory review of a combination flu and Covid shot. For a company burning cash and missing sales projections, “it’s very difficult for people to look at a delay of a year of a key revenue driver and not be concerned,” said Leerink analyst Mani Foroohar. Shares fell as much as 8.7 percent Thursday before recovering slightly.
-
1 week ago |
news.bloombergtax.com | Gerry Smith
Biogen Inc.’s chief executive officer said that the impact from US tariffs will be limited, as three-quarters of its product revenue comes from drugs made in the US. CEO Chris Viehbacher told analysts that “even if the exemption for pharmaceuticals were to be removed,” Biogen doesn’t expect a material impact from US tariffs this year. He added that the company’s guidance includes possible retaliatory tariffs from China. The company’s shares rose 0.3% at 9:44 a.m. in New York on Thursday.
-
1 week ago |
news.bloomberglaw.com | Gerry Smith
Biogen Inc.’s chief executive officer said that the impact from US tariffs will be limited, as three-quarters of its product revenue comes from drugs made in the US. CEO Chris Viehbacher told analysts that “even if the exemption for pharmaceuticals were to be removed,” Biogen doesn’t expect a material impact from US tariffs this year. He added that the company’s guidance includes possible retaliatory tariffs from China. The company’s shares rose 0.3% at 9:44 a.m. in New York on Thursday.
-
1 week ago |
bloomberg.com | Gerry Smith
Biogen Inc. headquarters in Cambridge, Massachusetts. Photographer: Adam Glanzman/Bloomberg(Bloomberg) -- Biogen Inc.’s chief executive officer said that the impact from US tariffs will be limited, as three-quarters of its product revenue comes from drugs made in the US. CEO Chris Viehbacher told analysts that “even if the exemption for pharmaceuticals were to be removed,” Biogen doesn’t expect a material impact from US tariffs this year.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 8K
- Tweets
- 772
- DMs Open
- No
RT @FayCortez: FDA leaders pushed Pfizer and Moderna to quickly file for full approval of their Covid shots for kids before President Trump…
The entire vaccine world is in turmoil, but Covid shots, especially for children, have become especially controversial in the Trump administration. https://t.co/UhEZZBzjX8
RT @g0ingmad: Scoop with @josh_wingrove: The White House is pulling its nomination for Janette Nesheiwat to be US surgeon general. This is…